Latest news
{{'2025-11-06T18:01:11Z' | dateFormatFilter}}
Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost
{{'2025-11-05T21:30:00Z' | dateFormatFilter}}
Novo Nordisk Wegovy® users achieved waist and BMI targets linked to improved health and low risk of obesity-related complications
{{'2025-11-05T13:15:00Z' | dateFormatFilter}}
Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors
Investors
Share price
{{priceData.date}} {{priceData.time}}
{{priceData.currentPrice}}
{{priceData.currency}}
Go to stock watch
{{priceData.change}} {{priceData.currency}}
